A retrospective study of patients with recurrent chronic atrophic candidosis

https://doi.org/10.1016/0030-4220(81)90312-1Get rights and content

Abstract

A retrospective study was carried out in thirty-seven patients who had recurrent chronic atrophic candidosis (CAC). The factors commonly believed to predispose to CAC were investigated, including corrected whole blood folate, iron saturation, and vitamin B12. The incidence of CAC based on clinical and microbiologic criteria was assessed before and after antifungal therapy and correction of predisposing factors. No significant difference was found. Hence, the role of additional, less well-known predisposing factors in the etiopathology of CAC should be considered when one is treating patients with recurrent, chronic Candida infections.

References (27)

  • J.C. Davenport et al.

    Incidence of Immediate and Delayed Hypersensitivity to Candida albicans in Denture Stomatitis

    J. Dent. Res

    (1971)
  • E. Budtz-Jörgensen

    Cellular Immunity in Acquired Palatal Candidiasis

    Scand. J. Dent. Res

    (1973)
  • T. Lehner
  • Cited by (34)

    • Effect of aPDT on Streptococcus mutans and Candida albicans present in the dental biofilm: Systematic review

      2018, Photodiagnosis and Photodynamic Therapy
      Citation Excerpt :

      The Candida species are present in the oral cavity of healthy individuals and Candida albicans is the most prevalent, reaching 60–70%, followed by Candida tropicalis and Candida glabrata [4]. These fungi are usually commensal, but in some situations, they can become parasitic, causing oral candidiasis [5,6]. Oral candidiasis has gained importance due to the increase in the number of immunocompromised individuals [7].

    • Novel mucoadhesive extended release tablets for treatment of oral candidosis: "In vivo" evaluation of the biopharmaceutical performance

      2009, Journal of Pharmaceutical Sciences
      Citation Excerpt :

      However, these standard dosages imply the administration of large quantities of drug over very long periods of time. Furthermore, in spite of its efficacy in vitro, treatment with N can fail in vivo.6,7 The design of mucoadhesive forms to retain the device in the oral cavity during the period of delivery, together with a sustained release of the drug to keep its concentration within the therapeutic range, are valid approaches in order to overcome the shortcomings of conventional treatments.8,9

    View all citing articles on Scopus

    Lecturer, Department of Oral Medicine and Pathology, University of Glasgow.

    ∗∗

    Senior Lecturer, Department of Oral Medicine and Pathology, University of Glasgow.

    View full text